Ensysce Biosciences has partnered with Quotient Sciences to develop an opioid to prevent abuse and overdose, enabling it to make mid-study changes to the formulation based on emerging data.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
An expert from the company discusses how ever-changing patient needs and other dynamic factors are likely to impact pharma ingredient trends down the road.
The synthetic biology company which specializes in producing ingredients for plant-inspired medicines has a pilot-scale manufacturing facility in the works.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The group’s latest report glimpses inside the minds of pharma leaders, who are looking at a product’s full life-cycle development at the preclinical stage.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.
The contract development and manufacturing organization plans to invest €7.3m to expand and upgrade API production capacity at its Mourenx, France facility.
This month’s announcements on new products, tech partnerships, and more includes DiMe, Evonik, Advarra, Curebase, ObvioHealth, and other notable companies.
The biotechnology company has reported its candidate for treating amyotrophic lateral sclerosis patients has shown promising results in an early-phase study.
The contract development and manufacturing organization has begun fulfilling customer orders at its new clinical manufacturing facility in Rankweil, Austria.
A representative from life-science services company Azzur Group explains how flexibility and speed can help in reaching the best solution more efficiently.
This month’s announcements of launches, appointments, and partnerships includes Saama, COTA, Yourway, Eversana, Kindeva, and other notable industry companies.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.
Efanesoctocog alfa is an investigational factor III therapy designed to prevent bleeds and bleeding episodes in patients diagnosed with the rare disorder.
This month’s announcements of awards, investments, executive appointment, and expansions include Javara, Thread, uMotif, Lonza, and other notable companies.
Lithuania’s life sciences industry is growing at one of the fastest rates in Europe. Ahead of BIO, Innovation Agency Lithuania explains what the country’s plans are for future growth in the area and how this is built upon students heading into STEM studies.
Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohn’s.
The approval is the first that the Food and Drug Administration has granted for a drug intended to treat eosinophilic esophagitis, a chronic immune disorder.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
The US agency has approved Enhertu for patients diagnosed with HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
The CRO has paired with the drug discovery technology firm on Logica, an artificial intelligence tool designed to accelerate development of new treatments.
The thin-film freezing specialist reports positive safety and pharmacokinetic data coming out of the Phase I trial of its niclosamide inhalation powder.
This month’s news on partnerships, appointments, expansions, and investment includes Javara, ACG, Phastar, Elligo Health Research, and other notable companies.
An expert from the organization discusses ahead of his CPhI North America presentation how tomorrow’s drugs can’t all be formulated with yesterday’s excipients.
An expert from Pharmatech Associates offers a glimpse into the evolution of CM and previews a lively discussion during the upcoming CPhI North America event.
A leader from the organizer of the pharmaceutical event discusses what’s in store for the upcoming conference, and for the drug development industry itself.
The agency has approved an expanded indication for Qelbree extended-release capsules to treat attention deficit hyperactivity disorder in younger patients.
Newly launched life sciences company Sionna Therapeutics has secured funding to fuel discovery and development of drug candidates to treat cystic fibrosis.
The US agency has expanded its approval of Veklury to include use in pediatric patients 28 days and older who have tested positive for the COVID-19 virus.
The company’s Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.
The 2022 edition of the Highly Potent Active Pharmaceutical Ingredients Summit (June 28 to 30 in Boston) will take on a range of topics, including safety.
The US Food and Drug Administration has approved a move to make the oral lead-in period for ViiV Healthcare’s once-every-other-month drug Cabenuva optional.
Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.
The pharma manufacturing specialist is increasing capacity at its development and manufacturing labs to meet growing global demand for highly potent APIs.
An expert from the health tech company explains how AI, natural language processing, and other tools can improve pharmaceutical product safety reporting.
